• NewAmsterdam Pharma secured a positive CHMP opinion backing EU approval for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe) in primary hypercholesterolemia.
• The European Commission decision is expected in the second half of 2026.
• Menarini holds exclusive commercialization rights for obicetrapib in Europe under the partners’ licensing deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via PR Newswire (Ref. ID: GE11730) on July 26, 2026, and is solely responsible for the information contained therein.